These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 29675979)

  • 1. Senescent cells re-engineered to express soluble programmed death receptor-1 for inhibiting programmed death receptor-1/programmed death ligand-1 as a vaccination approach against breast cancer.
    Chen Z; Hu K; Feng L; Su R; Lai N; Yang Z; Kang S
    Cancer Sci; 2018 Jun; 109(6):1753-1763. PubMed ID: 29675979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
    Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
    Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.
    Kodumudi KN; Ramamoorthi G; Snyder C; Basu A; Jia Y; Awshah S; Beyer AP; Wiener D; Lam L; Zhang H; Greene MI; Costa RLB; Czerniecki BJ
    Front Immunol; 2019; 10():1939. PubMed ID: 31475002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Soluble PD-1 over-expression enhances the anti-tumor effect of senescence tumor cell vaccine against breast cancer cell growth in tumor-bearing mice].
    Chen Z; Lin H; Hu K; Su R; Lai N; Yang Z; Kang S
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Jan; 38(1):20-26. PubMed ID: 33177023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.
    Zhang X; Shi X; Li J; Hu Z; Gao J; Wu S; Long Z
    Cancer Sci; 2019 Jan; 110(1):31-39. PubMed ID: 30343514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect.
    Liu C; Lu Z; Xie Y; Guo Q; Geng F; Sun B; Wu H; Yu B; Wu J; Zhang H; Yu X; Kong W
    Immunol Lett; 2018 Aug; 200():33-42. PubMed ID: 29894719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monocyte-Derived Dendritic Cells with Silenced PD-1 Ligands and Transpresenting Interleukin-15 Stimulate Strong Tumor-Reactive T-cell Expansion.
    Van den Bergh JMJ; Smits ELJM; Berneman ZN; Hutten TJA; De Reu H; Van Tendeloo VFI; Dolstra H; Lion E; Hobo W
    Cancer Immunol Res; 2017 Aug; 5(8):710-715. PubMed ID: 28637876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
    Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
    Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1
    Li X; Du H; Zhan S; Liu W; Wang Z; Lan J; PuYang L; Wan Y; Qu Q; Wang S; Yang Y; Wang Q; Xie F
    Front Immunol; 2022; 13():830606. PubMed ID: 35935985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
    Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B
    Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice.
    Ge Y; Xi H; Ju S; Zhang X
    Cancer Lett; 2013 Aug; 336(2):253-9. PubMed ID: 23523609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1.
    Song MY; Park SH; Nam HJ; Choi DH; Sung YC
    J Immunother; 2011 Apr; 34(3):297-306. PubMed ID: 21389868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response.
    Shin SP; Seo HH; Shin JH; Park HB; Lim DP; Eom HS; Bae YS; Kim IH; Choi K; Lee SJ
    Mol Ther; 2013 Mar; 21(3):688-95. PubMed ID: 23337984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine.
    Shi X; Zhang X; Li J; Mo L; Zhao H; Zhu Y; Hu Z; Gao J; Tan W
    Int J Cancer; 2018 May; 142(10):2106-2117. PubMed ID: 29243219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-affinity human programmed death-1 ligand-1 variant promotes redirected T cells to kill tumor cells.
    Liang Z; Li Y; Tian Y; Zhang H; Cai W; Chen A; Chen L; Bao Y; Xiang B; Kan H; Li Y
    Cancer Lett; 2019 Apr; 447():164-173. PubMed ID: 30677447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
    Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
    Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells.
    Pen JJ; Keersmaecker BD; Heirman C; Corthals J; Liechtenstein T; Escors D; Thielemans K; Breckpot K
    Gene Ther; 2014 Mar; 21(3):262-71. PubMed ID: 24401835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8
    Zahm CD; Colluru VT; McNeel DG
    Cancer Immunol Res; 2017 Aug; 5(8):630-641. PubMed ID: 28634215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
    Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
    [No Abstract]   [Full Text] [Related]  

  • 20. B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets.
    Mkrtichyan M; Najjar YG; Raulfs EC; Liu L; Langerman S; Guittard G; Ozbun L; Khleif SN
    J Immunol; 2012 Sep; 189(5):2338-47. PubMed ID: 22837483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.